BIB_329
Gaudy-Marqueste C et al. (Aix-Marseille + French multicentre cohort). Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma: real-world retrospective. Ann Oncol July 2025. PMID 40204154. Key finding: adjuvant anti-PD-1 did NOT significantly improve RFS/DMFS vs observation at Stage IIIA; adjuvant BRAF/MEKi shows promise. Likely to drive 2026-2027 guideline-revisiting at Stage IIIA. [Tasks: 17, 19b] Tier: 2 (real-world retrospective) Grade: B Retrieved: 2026-05-15
- Evidence grade
- B
- Tier
- 2 (real-world retrospective)
- Cited by tasks
- 17, 19b
- Identifiers
- PMID:40204154
↗ Follow the original source for full context
Full extracted findings & patient-implication analysis: bibliography/BIB_329/findings.md (research corpus). This page is a short context summary — not individualised medical advice.